ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program-Reference-Cited by-同舟云学术

ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program

Published:2003-06 Issue:3 Volume:40 Page:301-307
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Pallis A.G.,Mavroudis D.,Androulakis N.,Souglakos J.,Kouroussis C.,Bozionelou V.,Vlachonikolis I.G.,Georgoulias V.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference39 articles.

1. Epidermal growth factor receptor family in lung cancer and premalignancy;Franklin;Semin. Oncol.,2002

2. Kinase inhibitors in cancer therapy: a look ahead;Sedlacek;Drugs,2000

3. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression;Rusch;Clin. Cancer Res.,1997

4. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I–IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival;Fontanini;Clin. Cancer Res.,1998

5. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer;Fujino;Eur. J. Cancer,1996

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Imaging analysis of EGFR mutated cancer cells using peptide nucleic acid (PNA)–DNA probes;The Analyst;2019

2. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study;The Lancet Respiratory Medicine;2017-11

3. Exposure–Response Relationships of Anticancer Agents: Application in Drug Development and Drug Label;Cancer Drug Discovery and Development;2013-11-30

4. Lung Cancer Genotype-Based Therapy and Predictive Biomarkers: Present and Future;Archives of Pathology & Laboratory Medicine;2012-12-01

5. Off-Target Serine/Threonine Kinase 10 Inhibition by Erlotinib Enhances Lymphocytic Activity Leading to Severe Skin Disorders;Molecular Pharmacology;2011-05-23